Login to Your Account



AC Immune gets $22M for tau-targeting Alzheimer’s vaccine

By Cormac Sheridan
Staff Writer

Friday, January 10, 2014
AC Immune SA raised CHF20 million (US$22 million) in a Series D round that will fund clinical development of a therapeutic vaccine for Alzheimer’s disease, ACI-35, which targets a phosphorylated species of tau protein thought to be involved in the progression of the condition.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription